上海
分享至
财联社8月5日电，泽璟制药公告，公司近日收到国家药监局核准签发的《药物临床试验批准通知书》，注射用ZG005与注射用ZGGS18联合用于晚期实体瘤的临床试验获得批准。同日公告，注射用ZG005与贝伐珠单抗联合用于晚期肝细胞癌的临床试验获得批准。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
